Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
1353(c) 1355(c) 1359.2(c) 1353.2(c) 1358(c) Last
7 512 929 11 776 369 12 284 712 15 596 977 9 856 926 Volume
0.00% +0.15% +0.31% -0.44% +0.35% Change
More quotes
Financials ( GBP)
Sales 2017 30 081 M
EBIT 2017 8 302 M
Net income 2017 3 592 M
Debt 2017 13 830 M
Yield 2017 5,91%
Sales 2018 30 431 M
EBIT 2018 8 306 M
Net income 2018 4 255 M
Debt 2018 13 520 M
Yield 2018 5,91%
P/E ratio 2017 19,27
P/E ratio 2018 15,24
EV / Sales2017 2,69x
EV / Sales2018 2,65x
Capitalization 67 091 M
More Financials
Company
‘GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products.It operates through the following segments: Pharmaceuticals, Pharmaceuticals... 
Sector
Pharmaceuticals
Calendar
02/07Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
03:55p En route to Davos, Macron makes Versailles the place to be
09:38a GLAXOSMITHKLINE : 19.8% Potential Upside Indicated by Liberum Capital
08:13a GLAXOSMITHKLINE : UK-based drugmaker GlaxoSmithKline mulls Kenya staff cuts
07:51a GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc Provides New Data about Comb..
07:49a GLAXOSMITHKLINE : Recent Findings from GlaxoSmithKline plc Has Provided New Info..
01:20a At AstraZeneca, fewer drug projects bring big productivity jump
01/18 GLAXOSMITHKLINE EYES $1.7B BID FOR R : report
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/15 GLAXOSMITHKLINE : National Institutes of Health - Brian Berridge tapped to manag..
01/13 GLAXOSMITHKLINE : Brian Berridge Tapped to Manage National Toxicology Program
More news
Sector news : Pharmaceuticals - NEC
03:55p En route to Davos, Macron makes Versailles the place to be
11:16a SHIRE PLC SHIRE PLC : Directorate Change
01:20a At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
01/18 ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on GLAXOSMITHKLINE 
GLAXOSMITHKLINE  - 2015
This could be the time to buy
BUY
GLAXOSMITHKLINE - 2014
Bearish signal below GBp 1415
SELL
More Strategies
Latest Tweets
06:51a$GSK - GlaxoSmithKline plc #GSK Forecasted to Post FY2022 Earnings of $3.75 P.. 
05:59aGlaxoSmithKline plc to Post FY2022 Earnings of $3.75 Per Share, Jefferies Gro.. 
05:58aJefferies Group Sets GlaxoSmithKline FY2022 Earnings Estimates at $3.75 EPS. .. 
01/18GlaxoSmithKline CEO Continues Restructuring With Job Cuts in Africa  
01/18Jefferies Group Raises GlaxoSmithKline FY2017 Earnings Estimates to $3.06 EPS.. 
More tweets
Qtime:243
News from SeekingAlpha
01/18 Big Biopharma in the red in early trade
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 NeuroMetrix inks deal with Glaxo for Quell ex-U.S.; shares ahead 68% premarke..
01/16 STOCKS FOR 2018 : Beaten Down, With Dividends, And Recession Resistant
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 15,5  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE2.32%93 292
JOHNSON & JOHNSON5.20%394 704
NOVARTIS0.61%224 711
PFIZER2.65%220 487
ROCHE HOLDING LTD.-5.40%210 743
MERCK AND COMPANY10.24%166 723